Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.

https://doi.org/10.1182/hematology.2019000077

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.

https://doi.org/10.1182/hematology.2019000029

Published: 2019

Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.

https://doi.org/10.1182/hematology.2019000030

Published: 2019

Journal Articles

Where does PD-1 blockade fit in HL therapy?

Alex F. Herrera

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 213–220.

https://doi.org/10.1182/asheducation-2018.1.213

Published: 2018

Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.

https://doi.org/10.1182/asheducation-2018.1.200

Published: 2018

Journal Articles

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Alison J. Moskowitz

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 207–212.

https://doi.org/10.1182/asheducation-2018.1.207

Published: 2018

Journal Articles

Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond

Stephen M. Ansell

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 618–621.

https://doi.org/10.1182/asheducation-2017.1.618

Published: 2017

Journal Articles

Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies

Kieron Dunleavy

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 298–303.

https://doi.org/10.1182/asheducation-2017.1.298

Published: 2017

Journal Articles

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma

W. Robert Liu, Margaret A. Shipp

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 310–316.

https://doi.org/10.1182/asheducation-2017.1.310

Published: 2017

Journal Articles

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Nancy L. Bartlett

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 317–323.

https://doi.org/10.1182/asheducation-2017.1.317

Published: 2017

Journal Articles

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Craig Moskowitz

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 331–338.

https://doi.org/10.1182/asheducation-2016.1.331

Published: 2016

Journal Articles

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment

Flora E. van Leeuwen, Andrea K. Ng

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 323–330.

https://doi.org/10.1182/asheducation-2016.1.323

Published: 2016

Journal Articles

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Peter W. M. Johnson

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 316–322.

https://doi.org/10.1182/asheducation-2016.1.316

Published: 2016

Journal Articles

Hodgkin lymphoma in children and adolescents: improving the therapeutic index

Kara M. Kelly

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 514–521.

https://doi.org/10.1182/asheducation.V2015.1.514.3917878

Published: 2015

Journal Articles

Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology Am Soc Hematol Educ Program. 2014;2014: 135-143 .

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 652.

https://doi.org/10.1182/asheducation.V2015.1.652.3918153

Published: 2015

Journal Articles

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Solomon A. Graf, Ajay K. Gopal

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 151–157.

https://doi.org/10.1182/asheducation-2014.1.151

Published: 2014

Journal Articles

The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling

David W. Scott, Christian Steidl

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 144–150.

https://doi.org/10.1182/asheducation-2014.1.144

Published: 2014

Journal Articles

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Andrew M. Evens, Lale Kostakoglu

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 135–143.

https://doi.org/10.1182/asheducation-2014.1.135

Published: 2014

Journal Articles

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Andrea K. Ng

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 488–494.

https://doi.org/10.1182/asheducation-2014.1.488

Published: 2014

NARROW

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Management of older Hodgkin lymphoma patients

Novel agents and immune invasion in Hodgkin lymphoma

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Where does PD-1 blockade fit in HL therapy?

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond

Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Hodgkin lymphoma in children and adolescents: improving the therapeutic index

Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology Am Soc Hematol Educ Program. 2014;2014: 135-143 .

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only